Altimmune (ALT) Other Non-Current Liabilities (2010 - 2026)

Altimmune (ALT) has reported Other Non-Current Liabilities for 17 consecutive years, with $5.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 36243.75% year-over-year to $5.8 million; the TTM figure through Mar 2026 stood at $5.8 million (up 36243.75% YoY), while the FY2025 annual figure was $5.8 million, up 7.94% from the prior year.
• Other Non-Current Liabilities rose to $5.8 million in Q1 2026 per ALT's latest filing, from $5.8 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $5.8 million in Q1 2026 and bottomed at $16000.0 in Q1 2025.
• Historically, Other Non-Current Liabilities has averaged $2.7 million across 5 years, with a median of $2.2 million in 2022.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities slumped 99.01% — and 2026, when it surged 36243.75%.
• Altimmune's Other Non-Current Liabilities stood at $60000.0 in 2022, then plunged by 33.33% to $40000.0 in 2023, then jumped by 13225.0% to $5.3 million in 2024, then gained by 7.94% to $5.8 million in 2025, then grew by 1.08% to $5.8 million in 2026.
• Business Quant data shows ALT's Other Non-Current Liabilities at $5.8 million in Q1 2026, $5.8 million in Q4 2025, and $5.8 million in Q3 2025.